• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在破伤风、白喉和百日咳联合疫苗（Tdap）接种部位出现的蓝痣：病例报告及疫苗相关皮肤病变综述

Blue Nevus Developing at a Combined Tetanus, Diphtheria, and Pertussis (Tdap) Vaccination Site: Case Report and Summary of Vaccine-Associated Cutaneous Lesions.

作者信息

Kim Yoo Jung, Cohen Philip R

机构信息

Dermatology, Stanford University, Stanford, USA.

Dermatology, San Diego Family Dermatology, National City, USA.

出版信息

Cureus. 2019 Jun 25;11(6):e4997. doi: 10.7759/cureus.4997.

DOI:10.7759/cureus.4997
PMID:31497428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6707821/
Abstract

Skin reaction may develop at the site of vaccine administration. A 54-year-old woman who developed a cellular blue nevus at the site of the combined tetanus, diphtheria, and acellular pertussis (Tdap) vaccine injection four years prior to presentation is described. In addition to blue nevus, other reactions at combined tetanus, diphtheria, and pertussis vaccine injection sites include abscess, deep reactive nodular infiltrates of mixed inflammation, and necrotizing granuloma. In conclusion, blue nevus can be added to the list of cutaneous events that can occur at Tdap vaccination sites.

摘要

皮肤反应可能在疫苗接种部位出现。本文描述了一名54岁女性，在接种破伤风、白喉和无细胞百日咳联合疫苗（Tdap）四年后，接种部位出现了细胞性蓝痣。除了蓝痣外，破伤风、白喉和百日咳联合疫苗接种部位的其他反应还包括脓肿、混合性炎症的深部反应性结节浸润和坏死性肉芽肿。总之，蓝痣可被列入Tdap疫苗接种部位可能出现的皮肤病变清单中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e22a/6707821/0c492579ee34/cureus-0011-00000004997-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e22a/6707821/0c492579ee34/cureus-0011-00000004997-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e22a/6707821/0c492579ee34/cureus-0011-00000004997-i01.jpg

相似文献

1
Blue Nevus Developing at a Combined Tetanus, Diphtheria, and Pertussis (Tdap) Vaccination Site: Case Report and Summary of Vaccine-Associated Cutaneous Lesions.在破伤风、白喉和百日咳联合疫苗（Tdap）接种部位出现的蓝痣：病例报告及疫苗相关皮肤病变综述
Cureus. 2019 Jun 25;11(6):e4997. doi: 10.7759/cureus.4997.
2
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.青少年首针加强免疫 10 年后接种含低含量抗原白喉破伤风联合无细胞百日咳疫苗的二价加强免疫的免疫原性和安全性：一项开放、III 期、非随机、多中心研究。
Hum Vaccin Immunother. 2018;14(8):1977-1986. doi: 10.1080/21645515.2018.1460292. Epub 2018 May 10.
3
A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.一项关于破伤风、白喉和无细胞百日咳（Tdap）疫苗与破伤风和白喉（Td）疫苗作为健康成年人加强针时的安全性和免疫原性的随机、双盲、非劣效性临床试验比较。
Vaccine. 2012 Aug 10;30(37):5464-71. doi: 10.1016/j.vaccine.2012.06.073. Epub 2012 Jul 6.
4
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.一种基因失活的两组分无细胞百日咳疫苗，单独或与破伤风和低剂量白喉疫苗联合使用，在青少年中的 2/3 期、随机对照非劣效性试验。
Lancet Infect Dis. 2018 Jan;18(1):58-67. doi: 10.1016/S1473-3099(17)30612-6. Epub 2017 Oct 20.
5
Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.65 岁及以上成年人接种破伤风类毒素、白喉类毒素和无细胞百日咳疫苗（Boostrix(®)）：两项随机试验的结果。
Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31.
6
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.破伤风类毒素、白喉类毒素和无细胞百日咳疫苗（Tdap）在孕妇和非孕妇中的反应原性和免疫原性。
Vaccine. 2018 Oct 8;36(42):6354-6360. doi: 10.1016/j.vaccine.2018.07.012. Epub 2018 Sep 13.
7
Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).预防青少年破伤风、白喉和百日咳：破伤风类毒素、白喉类毒素含量降低的无细胞百日咳疫苗的使用——免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.
8
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.成人接种含低剂量抗原的白喉-破伤风-无细胞百日咳疫苗（Tdap）初免加强后 9 年，抗体持久性、安全性和免疫原性。
Vaccine. 2018 Oct 8;36(42):6325-6333. doi: 10.1016/j.vaccine.2018.08.051. Epub 2018 Sep 7.
9
Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.联合低抗原含量破伤风、白喉和无细胞百日咳（Tdap）疫苗相关结节性红斑：病例报告及疫苗相关性结节性红斑综述。
Dermatol Ther (Heidelb). 2013 Dec;3(2):191-7. doi: 10.1007/s13555-013-0035-9. Epub 2013 Nov 1.
10
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.一种破伤风、白喉、重组无细胞百日咳联合疫苗（TdaP）在泰国健康成年人中的安全性和免疫原性。
Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29.

引用本文的文献

1
Disseminated Eruptive Blue Nevi in a Young Adult Patient.一名年轻成年患者的播散性爆发性蓝痣
Cureus. 2020 Nov 2;12(11):e11298. doi: 10.7759/cureus.11298.

本文引用的文献

1
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).预防百日咳、破伤风和白喉的疫苗在美国：免疫实践咨询委员会（ACIP）的建议。
MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1.
2
Pertussis: History of the Disease and Current Prevention Failure.百日咳：疾病史与当前预防失败情况
Adv Exp Med Biol. 2016;934:77-82. doi: 10.1007/5584_2016_21.
3
Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites.
肺炎球菌疫苗接种后注射部位苔藓样皮炎：接种部位发生的皮肤状况报告与综述
Dermatol Ther (Heidelb). 2016 Jun;6(2):287-98. doi: 10.1007/s13555-016-0105-x. Epub 2016 Mar 17.
4
Licensed pertussis vaccines in the United States. History and current state.美国的获许可的百日咳疫苗。历史与现状。
Hum Vaccin Immunother. 2014;10(9):2684-90. doi: 10.4161/hv.29576. Epub 2014 Nov 6.
5
Injection site abscess due to Mycobacterium tuberculosis following DPT vaccination.
Indian J Tuberc. 2014 Jul;61(3):246-9.
6
Blue nevi and variants: an update.蓝色痣和变异：更新。
Arch Pathol Lab Med. 2011 Mar;135(3):327-36. doi: 10.5858/2009-0733-RA.1.
7
The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites.免疫功能低下区：一个用于淋巴水肿、疱疹感染和其他受损部位的统一概念。
J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1364-73. doi: 10.1111/j.1468-3083.2009.03345.x. Epub 2009 Jun 22.
8
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine.在引入无细胞百日咳疫苗后，瑞典百日咳发病率下降。
Vaccine. 2003 May 16;21(17-18):2015-21. doi: 10.1016/s0264-410x(02)00777-6.
9
Postimmunization (vaccination) injection-site reactions. A report of four cases and review of the literature.
Am J Surg Pathol. 1993 May;17(5):516-24.